+86-27-65522453 sales@sun-shinechem.com

Mocetinostat(MGCD0103)

Catalog No.: 111015
Cas No.: 726169-73-9
Purity : 98% by HPLC/HNMR 
111015 - Mocetinostat(MGCD0103) | CAS 726169-73-9

Catalog number : 111015

CAS number : 726169-73-9

分子式 : C23H20N6O 

分子量 : 396.44 

Iupac 化学名称 : N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide 

Smile : O=C(NC1=CC=CC=C1N)C2=CC=C(CNC3=NC=CC(C4=CC=CN=C4)=N3)C=C2

InChiKey : HRNLUBSXIHFDHP-UHFFFAOYSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDS电话:+86-27-65522453 | Email:sales@sun-shinechem.com
分子式C23H20N6O 
分子量396.44 
外观crystalline solid 
纯度98% by HPLC/HNMR 
可溶性Soluble in DMSO 
存储3 years -20ºCpowder 6 months-80ºCin solvent 
运输条件Shipped under ambient temperature. 
SmileO=C(NC1=CC=CC=C1N)C2=CC=C(CNC3=NC=CC(C4=CC=CN=C4)=N3)C=C2
InChiKeyHRNLUBSXIHFDHP-UHFFFAOYSA-N
InChiInChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
Coming soon.

Mocetinostat is an orally-bioavailable, spectrum-selective HDAC inhibitor. Mocetinostat has completed 13 clinical trials in more than 400 patients with a variety of hematologic malignancies and solid tumors. Mirati is currently conducting Phase 2 studies of mocetinostat as a single agent in patients with bladder cancer and DLBCL.

Mirati retains worldwide rights to mocetinostat with the exception of certain Asian territories where the program is partnered with Taiho.

 

726169-73-9 - Request Bulk Quote

×
726169-73-9 - Request Bulk Quote
Change